{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:49:18Z","timestamp":1782172158871,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canc\u00e9rop\u00f4le Nord-Ouest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04309-z","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:54:12Z","timestamp":1777701252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4910-7881","authenticated-orcid":false,"given":"Yasmine","family":"Chokry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-5871","authenticated-orcid":false,"given":"Anne-Claire","family":"Groo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-6179","authenticated-orcid":false,"given":"Sophie","family":"Corvaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7921-0857","authenticated-orcid":false,"given":"Ons","family":"Ben Hadj Hassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isis","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-0270","authenticated-orcid":false,"given":"Samuel","family":"Valable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-1861","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Malzert-Fr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"4309_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073\u2013113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106.","journal-title":"Neuro Oncol"},{"key":"4309_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"4309_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133357","volume":"10","author":"H Kempf","year":"2015","unstructured":"Kempf H, Bleicher M, Meyer-Hermann M. Spatio-temporal dynamics of hypoxia during radiotherapy. PLoS ONE. 2015;10:e0133357. https:\/\/doi.org\/10.1371\/journal.pone.0133357.","journal-title":"PLoS ONE"},{"key":"4309_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnci\/89.13.917","volume":"89","author":"BJ Trock","year":"1997","unstructured":"Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance. JNCI J Natl Cancer Inst. 1997;89:917\u201331. https:\/\/doi.org\/10.1093\/jnci\/89.13.917.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4309_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.biopha.2018.10.063","volume":"109","author":"X Zhang","year":"2019","unstructured":"Zhang X, Ding K, Wang J, Li X, Zhao P. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions. Biomed Pharmacother. 2019;109:39\u201346. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.063.","journal-title":"Biomed Pharmacother"},{"key":"4309_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O van Tellingen","year":"2015","unstructured":"van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1\u201312. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002.","journal-title":"Drug Resist Updat"},{"key":"4309_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00003495-199754040-00007","volume":"54","author":"JC Adkins","year":"1997","unstructured":"Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997;54:615\u201333. https:\/\/doi.org\/10.2165\/00003495-199754040-00007.","journal-title":"Drugs"},{"key":"4309_CR8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18432","author":"DR Guay","year":"1999","unstructured":"Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother. 1999. https:\/\/doi.org\/10.1345\/aph.18432.","journal-title":"Ann Pharmacother"},{"key":"4309_CR9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.24488","author":"X Lian","year":"2018","unstructured":"Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L. Anticancer properties of fenofibrate: a repurposing use. J Cancer. 2018. https:\/\/doi.org\/10.7150\/jca.24488.","journal-title":"J Cancer"},{"key":"4309_CR10","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.4161\/cc.21015","volume":"11","author":"A Wilk","year":"2012","unstructured":"Wilk A, Urbanska K, Grabacka M, Mullinax J, Marcinkiewicz C, Impastato D, et al. Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle. 2012;11:2660\u201371. https:\/\/doi.org\/10.4161\/cc.21015.","journal-title":"Cell Cycle"},{"key":"4309_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-014-1385-6","volume":"117","author":"E Binello","year":"2014","unstructured":"Binello E, Mormone E, Emdad L, Kothari H, Germano IM. Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells. J Neurooncol. 2014;117:225\u201334. https:\/\/doi.org\/10.1007\/s11060-014-1385-6.","journal-title":"J Neurooncol"},{"key":"4309_CR12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711281105","author":"D Panigrahy","year":"2008","unstructured":"Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barn\u00e9s CM, Fannon M, et al. PPAR\u03b1 agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci. 2008. https:\/\/doi.org\/10.1073\/pnas.0711281105.","journal-title":"Proc Natl Acad Sci"},{"key":"4309_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1128\/MCB.00562-14","volume":"35","author":"A Wilk","year":"2015","unstructured":"Wilk A, Wyczechowska D, Zapata A, Dean M, Mullinax J, Marrero L, et al. Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death. Mol Cell Biol. 2015;35:182\u201398. https:\/\/doi.org\/10.1128\/MCB.00562-14.","journal-title":"Mol Cell Biol"},{"key":"4309_CR14","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1002\/tox.23369","volume":"36","author":"C Lin","year":"2021","unstructured":"Lin C, Lai SW, Shen CK, Chen CW, Tsai CF, Liu YS, et al. Fenofibrate inhibits Hypoxia-inducible factor-1 alpha and Carbonic anhydrase expression through activation of AMP-activated protein kinase\/HO-1\/Sirt1 pathway in Glioblastoma cells. Environ Toxicol. 2021;36:2551\u201361. https:\/\/doi.org\/10.1002\/tox.23369.","journal-title":"Environ Toxicol"},{"key":"4309_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejps.2016.11.025","volume":"97","author":"AC Groo","year":"2017","unstructured":"Groo AC, De Pascale M, Voisin-Chiret AS, Corvaisier S, Since M, Malzert-Fr\u00e9on A. Comparison of 2 strategies to enhance Pyridoclax solubility: nanoemulsion delivery system versus salt synthesis. Eur J Pharm Sci. 2017;97:218\u201326. https:\/\/doi.org\/10.1016\/j.ejps.2016.11.025.","journal-title":"Eur J Pharm Sci"},{"key":"4309_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijpharm.2015.12.010","volume":"498","author":"E Gu\u00e9","year":"2016","unstructured":"Gu\u00e9 E, Since M, Ropars S, Herbinet R, Le Pluart L, Malzert-Fr\u00e9on A. Evaluation of the versatile character of a nanoemulsion formulation. Int J Pharm. 2016;498:49\u201365. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.12.010.","journal-title":"Int J Pharm"},{"issue":"Suppl","key":"4309_CR17","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/0021-9150(94)05375-s","volume":"110","author":"A Munoz","year":"1994","unstructured":"Munoz A, Guichard JP, Reginault P. Micronised Fenofibrate. Atherosclerosis. 1994;110(Suppl):S45-48. https:\/\/doi.org\/10.1016\/0021-9150(94)05375-s.","journal-title":"Atherosclerosis"},{"key":"4309_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1208\/s12249-017-0840-z","volume":"19","author":"R Kumar","year":"2018","unstructured":"Kumar R, Siril PF. Enhancing the solubility of Fenofibrate by nanocrystal formation and encapsulation. AAPS PharmSciTech. 2018;19:284\u201392. https:\/\/doi.org\/10.1208\/s12249-017-0840-z.","journal-title":"AAPS PharmSciTech"},{"key":"4309_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jddst.2016.06.013","volume":"35","author":"R Berthelsen","year":"2016","unstructured":"Berthelsen R, Byrialsen JP, Holm R, Jacobsen J, Abrahamsson B, Saabye L, et al. Development of a \u03bcDissolution-Permeation model with in situ drug concentration monitoring. J Drug Deliv Sci Technol. 2016;35:223\u201333. https:\/\/doi.org\/10.1016\/j.jddst.2016.06.013.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4309_CR20","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1007\/s13277-014-3024-4","volume":"36","author":"D Han","year":"2015","unstructured":"Han D, Zhang J, Wei W, Tao T, Hu Q, Wang Y, et al. Fenofibrate induces G0\/G1 phase arrest by modulating the PPAR\u03b1\/FoxO1\/p27 kip pathway in human Glioblastoma cells. Tumour Biol. 2015;36:3823\u20139. https:\/\/doi.org\/10.1007\/s13277-014-3024-4.","journal-title":"Tumour Biol"},{"key":"4309_CR21","first-page":"233","volume":"66","author":"M Grabacka","year":"2015","unstructured":"Grabacka M, Waligorski P, Zapata A, Blake DA, Wyczechowska D, Wilk A, et al. Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier. J Physiol Pharmacol. 2015;66:233\u201347.","journal-title":"J Physiol Pharmacol"},{"key":"4309_CR22","doi-asserted-by":"publisher","unstructured":"Jin L, Hua H, Ji Y, Jia Z, Peng M, Huang S. Anti-inflammatory role of fenofibrate in treating diseases. Biomol Biomed. 2023;23:376\u201391. https:\/\/doi.org\/10.17305\/bb.2022.8534","DOI":"10.17305\/bb.2022.8534"},{"key":"4309_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119673","volume":"1871","author":"R Shaw","year":"2024","unstructured":"Shaw R, Basu M, Karmakar S, Ghosh MK. MGMT in TMZ-based glioma therapy: multifaceted insights and clinical trial perspectives. Biochim Biophys Acta Mol Cell Res. 2024;1871:119673. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119673.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"4309_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7030069","volume":"7","author":"H Strobel","year":"2019","unstructured":"Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, et al. Temozolomide and other alkylating agents in Glioblastoma therapy. Biomedicines. 2019;7:69. https:\/\/doi.org\/10.3390\/biomedicines7030069.","journal-title":"Biomedicines"},{"key":"4309_CR25","first-page":"2725","volume":"8","author":"DB Bocangel","year":"2002","unstructured":"Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8:2725\u201334.","journal-title":"Clin Cancer Res"},{"key":"4309_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bjc.6605712","volume":"103","author":"KA van Nifterik","year":"2010","unstructured":"van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RDM, et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer. 2010;103:29\u201335. https:\/\/doi.org\/10.1038\/sj.bjc.6605712.","journal-title":"Br J Cancer"},{"key":"4309_CR27","doi-asserted-by":"publisher","first-page":"35161","DOI":"10.1074\/jbc.M112.367367","volume":"287","author":"J Zhou","year":"2012","unstructured":"Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE, et al. Activation of Peroxisome Proliferator-activated Receptor \u03b1 (PPAR\u03b1) Suppresses Hypoxia-inducible Factor-1\u03b1 (HIF-1\u03b1) Signaling in Cancer Cells*. J Biol Chem. 2012;287:35161\u20139. https:\/\/doi.org\/10.1074\/jbc.M112.367367.","journal-title":"J Biol Chem"},{"key":"4309_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.5137\/1019-5149.JTN.17746-16.1","volume":"27","author":"H Li","year":"2017","unstructured":"Li H, Lei B, Xiang W, Wang H, Feng W, Liu Y, et al. Differences in protein expression between the u251 and u87 cell lines. Turk Neurosurg. 2017;27:894\u2013903. https:\/\/doi.org\/10.5137\/1019-5149.JTN.17746-16.1.","journal-title":"Turk Neurosurg"},{"issue":"1","key":"4309_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/jcr.1925.148","volume":"9","author":"O Warburg","year":"1925","unstructured":"Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9(1):148\u201363. https:\/\/doi.org\/10.1158\/jcr.1925.148.","journal-title":"J Cancer Res"},{"key":"4309_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176304","volume":"964","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xiao B, Liu Y, Wu S, Xiang Q, Xiao Y, et al. Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development. Eur J Pharmacol. 2024;964:176304. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176304.","journal-title":"Eur J Pharmacol"},{"key":"4309_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522392","volume":"15","author":"L Yang","year":"2025","unstructured":"Yang L, Li S, Yu L, Leng J, Li N. Targeting glycolysis: exploring a new frontier in glioblastoma therapy. Front Immunol. 2025;15:1522392. https:\/\/doi.org\/10.3389\/fimmu.2024.1522392.","journal-title":"Front Immunol"},{"key":"4309_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-004-6404-6","volume":"74","author":"CE Griguer","year":"2005","unstructured":"Griguer CE, Oliva CR, Gillespie GY. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol. 2005;74:123\u201333. https:\/\/doi.org\/10.1007\/s11060-004-6404-6.","journal-title":"J Neurooncol"},{"key":"4309_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/neuonc\/nos298","volume":"15","author":"V Miranda-Gon\u00e7alves","year":"2013","unstructured":"Miranda-Gon\u00e7alves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15:172\u201388. https:\/\/doi.org\/10.1093\/neuonc\/nos298.","journal-title":"Neuro Oncol"},{"key":"4309_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1515\/hsz-2012-0318","volume":"394","author":"A Corroyer-Dulmont","year":"2013","unstructured":"Corroyer-Dulmont A, P\u00e9r\u00e8s EA, Petit E, Durand L, Marteau L, Toutain J, et al. Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma. Biol Chem. 2013;394:529\u201339. https:\/\/doi.org\/10.1515\/hsz-2012-0318.","journal-title":"Biol Chem"},{"key":"4309_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/neuonc\/nos260","volume":"15","author":"A Corroyer-Dulmont","year":"2013","unstructured":"Corroyer-Dulmont A, P\u00e9r\u00e8s EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on \u00b5MRI and \u00b5PET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol. 2013;15:41\u201356. https:\/\/doi.org\/10.1093\/neuonc\/nos260.","journal-title":"Neuro Oncol"},{"key":"4309_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.599995","volume":"11","author":"Y Tan","year":"2021","unstructured":"Tan Y, Wang M, Yang K, Chi T, Liao Z, Wei P. PPAR-\u03b1 modulators as current and potential cancer treatments. Front Oncol. 2021;11:599995. https:\/\/doi.org\/10.3389\/fonc.2021.599995.","journal-title":"Front Oncol"},{"key":"4309_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1074911","volume":"13","author":"Y Lin","year":"2022","unstructured":"Lin Y, Wang Y, Li P. PPAR\u03b1: an emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases. Front Endocrinol (Lausanne). 2022;13:1074911. https:\/\/doi.org\/10.3389\/fendo.2022.1074911.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4309_CR38","doi-asserted-by":"publisher","unstructured":"Van den bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, et al. PPAR\u03b1-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma. Nat Commun. Nature Publishing Group. 2025;16:1237. https:\/\/doi.org\/10.1038\/s41467-025-56675-3","DOI":"10.1038\/s41467-025-56675-3"},{"key":"4309_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020736","author":"A Al Subait","year":"2025","unstructured":"Al Subait A, Alghamdi RH, Ali R, Alsharidah A, Huwaizi S, Alkhodier RA, et al. Discovery of PPAR alpha lipid pathway modulators that do not bind directly to the receptor as potential anti-cancer compounds. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26020736.","journal-title":"Int J Mol Sci"},{"key":"4309_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040621","volume":"11","author":"R Basilotta","year":"2022","unstructured":"Basilotta R, Lanza M, Casili G, Chisari G, Munao S, Colarossi L, et al. Potential therapeutic effects of PPAR ligands in glioblastoma. Cells. 2022;11:621. https:\/\/doi.org\/10.3390\/cells11040621.","journal-title":"Cells"},{"key":"4309_CR41","doi-asserted-by":"publisher","unstructured":"Koltai T. Fenofibrate in cancer: mechanisms involved in anticancer activity. F1000Research. 2015. https:\/\/doi.org\/10.12688\/f1000research.6153.2","DOI":"10.12688\/f1000research.6153.2"},{"key":"4309_CR42","doi-asserted-by":"publisher","unstructured":"Tan Y, Wang M, Yang K, Chi T, Liao Z, Wei P. PPAR-\u03b1 Modulators as current and potential cancer treatments. Front Oncol. Frontiers. 2021 [cited 2024 May 30];11. https:\/\/doi.org\/10.3389\/fonc.2021.599995","DOI":"10.3389\/fonc.2021.599995"},{"key":"4309_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2016.02.013","author":"G Quan","year":"2016","unstructured":"Quan G, Wu Q, Zhang X, Zhan Z, Zhou C, Chen B, et al. Enhancing in vitro dissolution and in vivo bioavailability of fenofibrate by solid self-emulsifying matrix combined with SBA-15 mesoporous silica. Colloids Surf B Biointerfaces. 2016. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.02.013.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4309_CR44","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1039\/C8RA01182F","volume":"8","author":"P Tipduangta","year":"2018","unstructured":"Tipduangta P, Takieddin K, F\u00e1bi\u00e1n L, Belton P, Qi S. Towards controlling the crystallisation behaviour of fenofibrate melt: triggers of crystallisation and polymorphic transformation. RSC Adv. 2018;8:13513\u201325. https:\/\/doi.org\/10.1039\/C8RA01182F.","journal-title":"RSC Adv"},{"key":"4309_CR45","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage K, Keating GM. Fenofibrate. Drugs. 2011;71:1917\u201346. https:\/\/doi.org\/10.2165\/11208090-000000000-00000.","journal-title":"Drugs"},{"key":"4309_CR46","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1523\/JNEUROSCI.23-15-06264.2003","volume":"23","author":"D Deplanque","year":"2003","unstructured":"Deplanque D, Gel\u00e9 P, P\u00e9trault O, Six I, Furman C, Bouly M, et al. Peroxisome Proliferator-Activated Receptor-\u03b1 activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-15-06264.2003.","journal-title":"J Neurosci"},{"key":"4309_CR47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.tranon.2019.04.006","volume":"12","author":"J Stalinska","year":"2019","unstructured":"Stalinska J, Zimolag E, Pianovich NA, Zapata A, Lassak A, Rak M, et al. Chemically modified variants of fenofibrate with antiglioblastoma potential. Transl Oncol. 2019;12:895\u2013907. https:\/\/doi.org\/10.1016\/j.tranon.2019.04.006.","journal-title":"Transl Oncol"},{"key":"4309_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.05.049","volume":"341","author":"P Li","year":"2007","unstructured":"Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm. 2007;341:1\u201319. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.05.049.","journal-title":"Int J Pharm"},{"key":"4309_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119655","volume":"587","author":"AC Groo","year":"2020","unstructured":"Groo AC, Hdir S, Since M, Brotin E, Weiswald LB, Paysant H, et al. Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer. Int J Pharm. 2020;587:119655. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119655.","journal-title":"Int J Pharm"},{"key":"4309_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121141","volume":"12","author":"L S\u00e9guy","year":"2020","unstructured":"S\u00e9guy L, Groo AC, Goux D, Hennequin D, Malzert-Fr\u00e9on A. Design of non-haemolytic nanoemulsions for intravenous administration of hydrophobic APIs. Pharmaceutics. 2020;12:1141. https:\/\/doi.org\/10.3390\/pharmaceutics12121141.","journal-title":"Pharmaceutics"},{"key":"4309_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101626","author":"L S\u00e9guy","year":"2021","unstructured":"S\u00e9guy L, Guyon L, Maurel M, Verdi\u00e9 P, Davis A, Corvaisier S, et al. Active targeted nanoemulsions for repurposing of tegaserod in alzheimer\u2019s disease treatment. MDPI. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13101626.","journal-title":"MDPI"},{"key":"4309_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.14791\/btrt.2022.0017","volume":"10","author":"GD Cha","year":"2022","unstructured":"Cha GD, Jung S, Choi SH, Kim DH. Local drug delivery strategies for Glioblastoma treatment. Brain Tumor Res Treat. 2022;10:151\u20137. https:\/\/doi.org\/10.14791\/btrt.2022.0017.","journal-title":"Brain Tumor Res Treat"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04309-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04309-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:30:01Z","timestamp":1782171001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04309-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4309"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04309-z","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}